CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel,
proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases,
announced today that it will host a conference call and webcast to provide a business update on May 17 at 4:30 pm ET. Live and
archived versions of the event can be accessed via the Company’s website.
Members of the Cue Biopharma executive management team will provide an overview of the Company’s Immuno-STAT™ (Immune Selective
Targeting and Alteration of T cells) platform and development strategy as well as updates on key programs and anticipated
milestones.
To access the webcast, visit the Events and Webcasts page within the Investor Relations section of the Company’s website at
www.cuebio.com. Please log on at least 15 minutes before the conference call to allow adequate
time should any software download or browser update be required to listen to the webcast. To join by phone, please call
866-679-9651 (domestic) or 409-231-2082 (international) and provide the conference call passcode 8471238.
A telephone replay will be available until 4:30 p.m. EDT on May 24, 2018. Access numbers for the telephone replay
are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 8471238. A webcast replay will also be archived
on www.cuebio.com for 45 days.
About Cue Biopharma
Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of injectable biologics engineered
to selectively modulate the human immune system to treat a broad range of cancers, chronic infectious diseases and autoimmune
disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient’s body, with the
goal of offering significant therapeutic benefits while potentially minimizing or eliminating unwanted side effects.
We believe our selective biologics allow us to target antigen-specific T cell populations in a variety of indications using a
peptide – MHC complex for delivering T cell modulating effectors, such as IL-2. Once a biologic has been optimized, our approach
offers the potential for readily exchanging peptides to target different T cell populations and indications using
previously-validated drug frameworks developed from the Immuno-STATTM platform. This flexibility could truncate the drug
selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and
cost-efficiently than current industry standard timelines and costs.
Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board
(SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
For more information, visit www.cuebio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor”
created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,”
“will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,”
“likely” or other comparable terms. All statements other than statements of historical facts included in this press release
regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements.
Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug
development efforts, including study results, our expectations regarding regulatory developments and expected future operating
results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to
the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many
of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements
include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability;
our ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for our product candidates
and the breadth of any approved indication; negative or inconclusive results from our clinical studies or serious and unexpected
drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in
regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the
FDA; our reliance on licensors, collaborations and strategic alliances; our ability to obtain adequate financing to fund our
business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's
Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form
10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is
based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result
of new information, future developments or otherwise.
Investor Contact:
John Woolford
Westwicke Partners
443-213-0506
Media Contact:
Cory Tromblee
Sam Brown Inc.
617-571-7220
